Compare TNON & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNON | SILO |
|---|---|---|
| Founded | 2012 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Apparel |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8M | 3.1M |
| IPO Year | 2021 | 2011 |
| Metric | TNON | SILO |
|---|---|---|
| Price | $2.98 | $1.49 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $44.38 | N/A |
| AVG Volume (30 Days) | ★ 915.4K | 43.2K |
| Earning Date | 11-12-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 84.90 | 57.98 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,944,000.00 | $72,102.00 |
| Revenue This Year | $46.86 | N/A |
| Revenue Next Year | $63.99 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 20.35 | N/A |
| 52 Week Low | $2.40 | $1.30 |
| 52 Week High | $50.40 | $19.92 |
| Indicator | TNON | SILO |
|---|---|---|
| Relative Strength Index (RSI) | 40.23 | 22.45 |
| Support Level | $2.54 | $1.30 |
| Resistance Level | $4.18 | $4.80 |
| Average True Range (ATR) | 0.24 | 0.11 |
| MACD | 0.09 | 0.05 |
| Stochastic Oscillator | 22.19 | 27.74 |
Tenon Medical Inc is a medical device company that has minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.